By Allen C. Ho, MD; and Robert L. Avery, MD
Anecdotal observations suggest ranibizumab may be a more effective treatment than bevacizumab for some retinal diseases.
By Jennifer Kreatsoulas, PhD, News & Contributing Editor
A summary of general medicine news that affects your patients, your practice, and you.
By Section Editor: David Boyer, MD
By Netan Choudhry, MD; and Kristine Pierce, MD; with contributions by John Loewenstein, MD
By Bruce Maller
By Michael D. Ober, MD
mTOR inhibitors: A new class of therapeutics.
By Pravin U. Dugel, MD
The CLEAR-IT 2 Extension Study was presented at the annual meeting of the Association for Research in Vision and Ophthalmology.
By Jeffrey S. Heier, MD
An assessment of the latest technology and its safety.
By Michael Bennett, MD; Gene Ng, MD, MBA; Ram Palanki, PharmD; and Karl Waite, MD
Phase 2 trial in patients with geographic atrophy shows safety, potential therapeutic effect.
By Glenn J. Jaffe, MD
By Scott W. Cousins, MD
Advanced diagnostic and imaging tools facilitate early disease recognition.
By Paul Garfinkle, MD
Anomalous posterior vitreous detachment is associated with dry AMD, and vitreomacular attachment with wet AMD.
By Susanne Binder, MD; Carl Glittenberg, MD; Christiane Falkner-Radler, MD; and Ilse Krebs, MD
Device uses coaxial concentric vacuum for fixation, aspiration.
By Michael A. Singer, MD
By Tom H Williamson, MD, MBChB, FRCS, FRCOphth
A new facility located above an ASC improves efficiency.
By Carl C. Awh, MD
David M. Brown, MD, is the director of the Greater Houston Retina Research Center and practices at Retina Consultants of Houston and The Methodist Hospital in Houston, TX.
By David M. Brown, MD
Both the 0.3 mg and 0.5 mg doses of ranibizumab (Lucentis, Genentech, Inc.) clinically and statistically improved vision in branch and central retinal vein occlusions (BRVO and CRVO) according to results of the Genentech-sponsored... more >
Injecting triamcinolone intravitreally appears effective in improving vision in some patients with retinal vein occlusion (RVO), according to results of the SCORE (Standard Care versus Corticosteroid for Retinal Vein Occlusion) St... more >
A sustained-release intravitreal 0.7-mg dexamethasone implant (Ozurdex, Allergan, Inc.) was well-tolerated and significantly improved vision in patients treated early compared with sham, according to data from identical multicente... more >
Intravitreal bevacizumab (Avastin; Genentech, Inc.) significantly improved vision in patients with diabetic macular edema (DME) compared with macular laser therapy, said Philip G. Hykin, MD, during his presentation at the Retina C... more >
advertisement
mTOR inhibitors: A new class of therapeutics.
by Pravin U. Dugel, MD
The CLEAR-IT 2 Extension Study was presented at the annual meeting of the Association for Research in Vision and Ophthalmology.
by Jeffrey S. Heier, MD
Anomalous posterior vitreous detachment is associated with dry AMD, and vitreomacular attachment with wet AMD.
by Susanne Binder, MD; Carl Glittenberg, MD; Christiane Falkner-Radler, MD; and Ilse Krebs, MD